This page contains a Flash digital edition of a book.
BIO


The Biotechnology Industry Organization represents a broad constituency of biotechnology and life sciences companies. LSIPR talks to BIO president and CEO Jim Greenwood about patent reform, healthcare, court cases and plans for the future.


Reform of the US patent system has been a long time coming. Year aſter year, it seems, US legislators get close to a consensus on satisfactory improvements to the patent system, only for their efforts to be scuppered by last- minute amendments, or other priorities, or just plain old disagreements. But this year, it might be different. A bill was approved earlier this year by the US Senate with broad bipartisan support. A similar bill is scheduled to be considered by the full House of Representatives in mid-June.


Assuming for now that the bill does get through in some form, what benefits would it bring to the biotechnology and life sciences industries? “BIO supports


legislation that removes subjective


elements of the patent system and provides a more reliable set of rules,” Greenwood says. “If patent reform is done in this way, the net effect will be positive.” Specifically, provisions to allow the US Patent and Trademark Office (USPTO) discretion to set its fees and keep collected fees should increase its resources and make it more effective, while harmonisation with the global norm on first-to-file will “bring us closer to a time when the same examination doesn’t have to be done in 15 countries”. Additionally, provisions to tackle the big-business bugbear of false patent marking suits will be welcome.


www.worldipreview.com


BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centres and related organisations across the United States and in more than 30 other countries. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also organises the BIO International Convention, the world’s largest biotechnology industry gathering, along with industry-leading investor and partnering meetings that are held around the world. For more information, visit www.bio.org


Life Sciences Intellectual Property Review 2011


11


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84